PMID- 34335679
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210803
IS  - 1664-8021 (Print)
IS  - 1664-8021 (Electronic)
IS  - 1664-8021 (Linking)
VI  - 12
DP  - 2021
TI  - Prognosis of Non-small-cell Lung Cancer Patients With Lipid Metabolism Pathway 
      Alternations to Immunotherapy.
PG  - 646362
LID - 10.3389/fgene.2021.646362 [doi]
LID - 646362
AB  - Immune checkpoint inhibitors (ICIs) significantly improve the survival of 
      patients with non-small-cell lung cancer (NSCLC), but only some patients obtain 
      clinical benefits. Predictive biomarkers for ICIs can accurately identify people 
      who will benefit from immunotherapy. Lipid metabolism signaling plays a key role 
      in the tumor microenvironment (TME) and immunotherapy. Hence, we aimed to explore 
      the association between the mutation status of the lipid metabolism pathway and 
      the prognosis of patients with NSCLC treated with ICIs. We downloaded the 
      mutation data and clinical data of a cohort of patients with NSCLC who received 
      ICIs. Univariate and multivariate Cox regression models were used to analyze the 
      association between the mutation status of the lipid metabolism signaling and the 
      prognosis of NSCLC receiving ICIs. Additionally, The Cancer Genome Atlas 
      (TCGA)-NSCLC cohort was used to explore the relationships between the different 
      mutation statuses of lipid metabolism pathways and the TME. Additionally, we 
      found that patients with high numbers of mutations in the lipid metabolism 
      pathway had significantly enriched macrophages (M0- and M1-type), CD4 + T cells 
      (activated memory), CD8 + T cells, Tfh cells and gamma delta T cells, 
      significantly increased expression of inflammatory genes [interferon-gamma (IFNG), 
      CD8A, GZMA, GZMB, CXCL9, and CXCL10] and enhanced immunogenic factors [neoantigen 
      loads (NALs), tumor mutation burden (TMB), and DNA damage repair pathways]. In 
      the local-NSCLC cohort, we found that the group with a high number of mutations 
      had a significantly higher tumor mutation burden (TMB) and PD-L1 expression. High 
      mutation status in the lipid metabolism pathway is associated with significantly 
      prolonged progression-free survival (PFS) in NSCLC, indicating that this marker 
      can be used as a predictive indicator for patients with NSCLC receiving ICIs.
CI  - Copyright (c) 2021 Cheng, Zhang, Liu, Lai and Wen.
FAU - Cheng, Tianli
AU  - Cheng T
AD  - Thoracic Medicine Department I, Hunan Cancer Hospital, Changsha, China.
AD  - Thoracic Medicine Department I, Affiliated Tumor Hospital of Xiangya Medical 
      School of Central South University, Changsha, China.
FAU - Zhang, Jing
AU  - Zhang J
AD  - HaploX Biotechnology, Shenzhen, China.
FAU - Liu, Danni
AU  - Liu D
AD  - HaploX Biotechnology, Shenzhen, China.
FAU - Lai, Guorong
AU  - Lai G
AD  - HaploX Biotechnology, Shenzhen, China.
FAU - Wen, Xiaoping
AU  - Wen X
AD  - Thoracic Medicine Department I, Hunan Cancer Hospital, Changsha, China.
AD  - Thoracic Medicine Department I, Affiliated Tumor Hospital of Xiangya Medical 
      School of Central South University, Changsha, China.
LA  - eng
PT  - Journal Article
DEP - 20210714
PL  - Switzerland
TA  - Front Genet
JT  - Frontiers in genetics
JID - 101560621
PMC - PMC8317604
OTO - NOTNLM
OT  - immune checkpoint inhibitors
OT  - immune microenvironment
OT  - lipid metabolism pathway
OT  - non-small-cell lung cancer
OT  - predictive marker
COIS- JZ, DL, and GL were employed by the company, HaploX Biotechnology. The remaining 
      authors declare that the research was conducted in the absence of any commercial 
      or financial relationships that could be construed as a potential conflict of 
      interest.
EDAT- 2021/08/03 06:00
MHDA- 2021/08/03 06:01
PMCR- 2021/07/14
CRDT- 2021/08/02 05:56
PHST- 2020/12/26 00:00 [received]
PHST- 2021/06/08 00:00 [accepted]
PHST- 2021/08/02 05:56 [entrez]
PHST- 2021/08/03 06:00 [pubmed]
PHST- 2021/08/03 06:01 [medline]
PHST- 2021/07/14 00:00 [pmc-release]
AID - 10.3389/fgene.2021.646362 [doi]
PST - epublish
SO  - Front Genet. 2021 Jul 14;12:646362. doi: 10.3389/fgene.2021.646362. eCollection 
      2021.